Helixmith is a clinical-stage biotech company valued less on the drugs it sells today than on the potential of the drug candidates it is developing. Its core asset is Engensis (VM202), a gene therapy that reached a U.S. Phase 3 trial for diabetic peripheral neuropathy. Current revenue comes from contract development and manufacturing and health functional foods, but the amounts are small (roughly ₩2.6 billion in 2025). Recent disclosures have been mostly routine and governance-related — annual results and quarterly reports — repeatedly confirming a broad picture of falling revenue and narrowing losses. What stands out is that its strengths are a Phase 3 pipeline, a third straight year of shrinking losses, and cash holdings that dwarf its short-term debt, giving it the financial staying power to keep its trials going. On the other hand, the core business is still running an operating loss, and because most of its value rests on a pre-market drug candidate, the shares can be volatile depending on trial outcomes and approval decisions.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue fell 47.8% year over year (3-year trend: mixed).
- Most recent quarter (Q1 2026) revenue was 40.4% lower than a year earlier.
- ROE is -0.3% (controlling-interest basis). It is above the sector average.
- Operating margin is -381.0%.
- P/E is hard to compute here, so this is read on P/B.
Ownership & governance As of 2025-12-31
Largest shareholder Biosolution 18.23% (corporate)
Controlling bloc incl. related parties 18.23%
With the controlling bloc holding 18%, control is maintained but the free float is relatively large.
🔎 In-depth analysis
- Helixmith earns money less from selling finished drugs than as a clinical-stage biotech whose value rests on drug candidates still in development.
- Its core asset is Engensis (VM202), a plasmid-DNA gene therapy that delivers the hepatocyte growth factor (HGF) gene into the body; it advanced to a Phase 3 trial in the United States for diabetic peripheral neuropathy (DPN).
- The company is also researching ways to broaden its use into conditions such as Charcot-Marie-Tooth disease (CMT) and amyotrophic lateral sclerosis (ALS).
- Its current revenue comes from contract development and manufacturing (CDMO) of cell and gene therapies, contract research (CRO) for trials and analysis, and B2B sales of natural-ingredient health functional foods and cosmetics — but the scale is small (about ₩2.6 billion in 2025), so most of its market capitalization is supported by the future value of its clinical candidates and its cash on hand.
- The latest closing price is ₩3,715 and the market capitalization is ₩171.2 billion.
- The price sits below both its 20-day moving average (₩4,219) and its 60-day line (₩6,386).
- Trading below both its short- and mid-term moving averages, the trend is on the soft side.
- The RSI (a technical gauge comparing upward and downward momentum over the past 14 days on a 0-100 scale) is 34.3, a neutral level.
- The price is down 16.9% over one month and down 51.7% over three months, and sits 60.8% below its 52-week high.
- Its relative strength versus the KOSDAQ is 66 (on a 1-99 scale that weights recent returns against the index over the past year more heavily; higher means stronger than the market), placing it in roughly the top 34% of all stocks by strength.
- Over the past three months it lagged the index by 45.9%.
- Chart readings are best interpreted alongside trading volume and disclosure dates.
- Because the company is running a loss, a P/E ratio (how many times a year's earnings the share price is worth) cannot be calculated, so the relevant asset-based metric is the P/B ratio (how many times net asset value per share the price is worth), at 1.31x.
- Net asset value per share (BPS) is about ₩3,092 and shareholders' equity is about ₩142.0 billion, meaning a large part of the market cap (about ₩186.7 billion) is backed by equity.
- Clinical-stage biotechs are hard to compare on earnings, so they are gauged on P/B against peers in the same situation (Medipost 1.37x, Anterogen 2.29x, Kangstem Biotech 3.02x, Genexine 0.45x); at 1.31x, Helixmith is lower than three of the four, so on an asset basis it is actually on the cheaper side.
- In particular, the current ratio (assets that can be converted to cash within a year against debts due within a year) reaches about 104x, meaning current assets (about ₩83.7 billion) vastly exceed short-term debt (about ₩0.8 billion) — a clear strength in terms of the financial staying power to fund trials.
- Because the core business is running an operating loss, P/B cannot be taken as an absolute measure of value, but the ample cash and below-peer asset multiple are better read as support than as a burden.
- Revenue was about ₩2.6 billion in 2025, down 47.8% from a year earlier, and fell a further 40.4% year on year in the first quarter of 2026, so the top line is shrinking.
- What matters, though, is the trajectory of the losses.
- The operating loss narrowed quickly for three straight years, from -₩35.2 billion in 2023 to -₩18.0 billion in 2024 to -₩9.9 billion in 2025, and the net loss also shrank sharply, from -₩6.4 billion to -₩1.5 billion to -₩0.4 billion.
- Even with small revenue, cost control is taking hold and losses are clearly narrowing.
- Because a turn to profit has not yet been confirmed, a forward P/E based on future earnings cannot be calculated — this reflects a lack of figures, not a lower assessment of value.
- Growth at a clinical-stage biotech is better read through pipeline progress and financial staying power than through revenue, and continued narrowing of losses means a correspondingly longer runway to carry the trials forward.
- Recent disclosures have centered on the February revenue and profit-structure change (annual results), the March business report (2025 finalized), and the May quarterly report (Q1 2026), repeatedly confirming the broad picture of falling revenue and narrowing losses.
- Governance-related disclosures such as the March annual general meeting and appointment of outside directors, along with an early-May large-holding report (a change in ownership stake), also followed.
- Rather than earnings-momentum disclosures such as new orders, supply contracts, or a turn to profit, routine reports and governance-oriented filings dominate — which suggests that near-term share drivers lie more on the side of clinical and pipeline progress.
- The picture for this stock is relatively clear.
- It holds a gene-therapy pipeline that has been carried through to Phase 3, its losses have shrunk for three straight years, and its cash and equivalents dwarf its short-term debt, giving it the financial staying power to keep the trials going.
- The share price also sits at a low spot among peers on an asset basis, so the equity-and-cash safety net is a clear strength.
- At the same time, the cautions are just as clear.
- The core business is still running an operating loss and revenue is falling, and because most of its value rests on a candidate that is not yet on the market, the shares are volatile depending on trial outcomes and approval decisions.
- Ultimately this is not a company to value on stable earnings but one driven by two variables: the odds of pipeline success and the time its cash can buy.
- It is strong when clinical and approval progress and cost control continue, and weak when trials stumble or cash burn accelerates.
🔎 Valuation vs peers Inconclusive
Compared on an asset basis (P/B) against a group of clinical-stage cell and gene therapy biotechs where P/E comparison is meaningless because all are loss-making.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| MEDIPOST | 0.00x | 1.34x | -34.29% |
| Anterogen | 0.00x | 1.72x | -1.57% |
| Kangstem Biotech | 0.00x | 3.24x | -15.27% |
| Genexine | 0.00x | 0.43x | -11.03% |
(a) The peer group is entirely loss-making, so no P/E can be derived; on P/B (price to net asset value per share), Helixmith at 1.58x is lower than Kangstem Biotech (3.45x) and Anterogen (2.9x), similar to Medipost (1.6x), and higher than Genexine (0.53x) — a middling level. (b) It is hard to read as a large discount or premium to equity. (c) A trailing P/E on last year's finalized results cannot be calculated at all because of the loss, and no official company forecast pointing to a turn to profit has been confirmed, so a forward multiple cannot be derived either. Accordingly, rather than declaring the shares cheap or expensive on an earnings multiple, it is more appropriate to view them through an asset and option lens — its equity, cash, and pipeline value — and to leave the verdict Inconclusive.
Price history Close · MA20 · MA60
The latest close is ₩3,715 and the market capitalization is ₩171.2 billion. The price sits below its 20-day moving average (₩4,219) and below its 60-day moving average (₩6,386). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 34.3, a neutral level. The one-month change is -16.9%, the three-month change is -51.7%, and the position relative to the 52-week high is -60.8%. Relative strength versus the KOSDAQ is 66 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 66% of all stocks. Over the past three months it lagged the index by 45.9%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -45.87% / 6M -28.66% / 12M +21.90%
Key metrics vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 1.21x is below the sector median (7.05x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
The operating margin is -381.0%. The debt ratio is 100.9%, so the financial structure is moderate.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $2.8M | $3.3M | $1.7M | -47.77% ↓ slower |
| Operating profit | -$23.4M | -$11.9M | -$6.6M | — |
| Net profit | -$42.5M | -$10.3M | -$288,257 | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $1.9M | $2.8M | $3.3M | $1.7M |
| Operating profit | -$32.2M | -$34.8M | -$23.4M | -$11.9M | -$6.6M |
| Net profit | -$33.8M | -$28.9M | -$42.5M | -$10.3M | -$288,257 |
| Revenue CAGR | 4-yr avg 2.91% | ||||
Revenue fell 47.8% year over year (2023 ₩4.2 billion → 2024 ₩5.0 billion → 2025 ₩2.6 billion), and the three-year trend is 'mixed'. The rate of decline widened from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 5 years on record, revenue compound annual growth (CAGR) is 2.9%. The two-year revenue CAGR is -21.4%. In the most recent quarter (Q1 2026), revenue was 40.4% lower than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- P/E and P/B are both low versus peers, so the price looks inexpensive relative to earnings and assets.
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
- Revenue fell 47.8% year over year (3-year trend: mixed).
Recent news & events searched · sourced
- 2026-05-15EarningsQ1 2026 quarterly report. Revenue of about ₩0.55 billion (-40.4% YoY), operating loss of -₩2.2 billion, and net loss of -₩1.41 billion, continuing the shrinking top line and core-business loss.In the near term it reconfirms falling revenue and continued losses. That said, the quarterly operating loss is contained relative to the past. Source
- 2026-05-04FilingReport on large holdings (general). A change in the stake of a major shareholder holding 5% or more was disclosed.Changes in the ownership structure are a reference point for supply-demand and governance, but are not directly linked to business results. Source
- 2026-03-20Earnings2025 business report. Annual revenue of about ₩2.6 billion (-47.8%), operating loss of -₩9.9 billion, and net loss of -₩0.44 billion, with the loss narrowing sharply from the prior year (-₩1.55 billion).In the medium term it confirms a trend of cost control and narrowing losses. Falling revenue, however, remains a challenge for rebuilding the top line. Source
- 2026-02-11EarningsDisclosure of a change in revenue or profit structure. Preliminary notice of 2025 annual revenue of about ₩2.6 billion, operating loss of -₩9.9 billion, and net loss of -₩0.4 billion, signaling a narrowing loss.An earnings-type disclosure that confirmed the narrowing-loss trend ahead of the business report. Source
Figure cross-check computed ↔ external
Recent filings
- 2026-05-15PeriodicQuarterly report
- 2026-05-04OwnershipOwnership-change filing
- 2026-03-30Disclosure
- 2026-03-30Shareholders' meeting notice
- 2026-03-20PeriodicAnnual business report
- 2026-03-18Audit report
- 2026-03-13Amended filing
- 2026-03-13Amended filing
- 2026-03-13Disclosure
- 2026-03-13Shareholders' meeting notice
- 2026-03-13Amended filing
- 2026-03-11Disclosure
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.